BioStem Raises $3M in Private Placement While $10M BioTissue Payment Remains Unpaid
BSEM sits 37% above its 52-week low of $2.251 on elevated volume (2.9× avg).
Summary
BioStem closed a $3 million private placement at $4.08 per share with warrants, while confirming its $10 million BioTissue Clearance Payment remains unpaid.
Key Events · Financing and Capital Events · BSEM
-
Private Placement Closed
Issued 735,296 shares at $4.08 per share with Series A and Series B warrants (each for 735,296 shares) at $3.83 exercise price, raising approximately $3.0 million gross proceeds.
-
Warrant Overhang
If all Series A and Series B warrants are exercised for cash, an additional 1.47 million shares would be issued, generating up to $5.6 million in additional proceeds.
-
BioTissue Clearance Payment Unpaid
The $10.0 million Clearance Payment owed to BioTissue for the Catalyze device remains unpaid as of the filing date, with ongoing discussions regarding timing and terms.
-
Placement Agent Compensation
H.C. Wainwright received a 7.0% cash fee and warrants to purchase 18,382 shares at $6.12 per share.
Analysis · BSEM · Life Sciences
A $3 million private placement closed on September 30, 2026, with 735,296 shares sold at $4.08 per share and warrants attached. Priced at-the-market under Nasdaq rules, the deal avoided a deep discount but still added significant potential dilution: if all Series A and Series B warrants are exercised, an additional 1.47 million shares would be issued, generating up to $5.6 million more in proceeds. Against that backdrop, the filing also confirms the $10 million Clearance Payment owed to BioTissue for the Catalyze device remains unpaid as of the filing date, with the company in ongoing discussions about timing and terms. The company had only $6.96 million in cash as of its last 10-Q, so this raise provides working capital but does not resolve the larger BioTissue obligation. The combination of a dilutive raise and an unresolved $10 million liability is material for a company with a going concern warning.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.4% of the 1070 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BSEM was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.1M. The 52-week trading range was $2.25 to $8.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.